NeuroSense Therapeutics Ltd. has reported that its experimental Alzheimer’s therapy PrimeC produced statistically significant reductions in multiple microRNAs associated with Alzheimer’s disease, according to the company.
In plasma samples from its Phase 2b PARADIGM trial, PrimeC significantly reduced levels of miR-146a-5p (p = 0.007), miR-21-5p (p = 0.003), miR-let-7a-5p (p = 0.028) and miR-let-7e-5p (p = 0.006) when compared to baseline values. The placebo group did not show significant changes over time, the company said.
The company claims these microRNAs are implicated in neuroinflammation, amyloid and tau pathology, and synaptic dysfunction—pathological features thought central to Alzheimer’s progression. Lowering those biomarkers, NeuroSense argues, supports PrimeC’s role as a disease-modifying therapy.
PrimeC is described as a fixed-dose extended-release oral combination of two FDA-approved drugs, ciprofloxacin and celecoxib, intended to target multiple mechanisms involved in neurodegeneration, including inflammation, iron accumulation and RNA regulation.
The PARADIGM trial enrolled 68 participants with amyotrophic lateral sclerosis (ALS) across Canada, Italy and Israel. Of these, 45 were randomized to PrimeC and 23 to placebo; after six months, all participants entered a 12-month open-label extension phase. Many participants remained on the ALS standard of care, riluzole, during the trial.
NeuroSense states that these biomarker findings will help inform the design of future Alzheimer’s trials and support its continued preparation toward Phase 3 development.
